1. Clinical Considerations in Evidence-based Management of GIST

3. Program Goals

4. GIST Current Treatment Paradigm

5. What is GIST?

6. What Causes GIST?

7. GIST: Treatment

8. Imatinib: Clinical Trial Results

9. Imatinib: Early Stage GIST

10. Resistance to Imatinib

11. Sunitinib

12. Regorafenib

13. Wild-type GIST (“Pediatric GIST”)

14. GIST Therapy: What Next?

15. Drug Interactions: Comparison

16. GIST Adverse Effects and Management Strategies

17. GIST: Optimizing Patient Outcomes

18. Hypertension

19. Hypertension (cont)

20. Other Cardiovascular Risks

21. Hand Foot Skin Reaction (HFSR)

22. Hand Foot Skin Reaction (HFSR) (cont)

23. Other Dermatologic Toxicities

24. Other Dermatologic Toxicities (cont)

25. Fatigue

26. Oral Toxicity

27. Diarrhea

28. Nausea

29. Laboratory Value Abnormalities

30. Unique to Imatinib

31. Unique to Regorafenib

32. Targeted Therapies for GIST: Comparison of Adverse Events (Grades 3-4)

33. GIST Encouraging Adherence to Therapy

34. Adherence to Therapy

35. Factors Associated With Non-Adherence to Oral Anticancer Therapy

36. Known Factors Associated With Non-Adherence to Oral Anticancer Therapy

37. Factors Associated With Non-Adherence to Oral Anticancer Therapy (cont)

38. Adherence With TKIs

39. Adherence With TKIs (cont)

40. Consider Over-adherence

41. Role of Nurse and Clinical Pharmacist

42. Role of Nurse and Clinical Pharmacist (cont)

43. Abbreviations

44. References (cont)

45. Abbreviations (cont)

46. References

47. References (cont)

48. References (cont)